Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer's disease?

Current Opinion in Investigational Drugs

Volumn 10, Issue 1, 2009, Pages 46-55

  Isingrini, E ^a   Desmidt, T ^a,b   Belzung, C ^a,c   Camus, V ^a,b,c  

^a CHRU de Tours   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

Aging; Alzheimer's disease; Depression; Endothelial dysfunction; Vascular disease; Vascular risk factor

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; KETOCONAZOLE; MEMANTINE; METYRAPONE; MIFEPRISTONE; NICERGOLINE; NIMODIPINE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL;

AGED; ALZHEIMER DISEASE; BRAIN BLOOD FLOW; DEPRESSION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; MENTAL DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; VASCULAR DISEASE;

AGED; ALZHEIMER DISEASE; AMYLOID; ANIMALS; BRAIN; DEPRESSION; DRUG DESIGN; ENDOTHELIUM, VASCULAR; HUMANS; VASCULAR DISEASES;

EID: 58449107369     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Yach D, Hawkes C, Gould CL, Hofman KJ: The global burden of chronic diseases: Overcoming impediments to prevention and control. J Am Med Assoc (2004) 291(21):2616-2622.
2. Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ: Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation (2007) 115(12):1544-1550.
3. Fagot-Campagna A, Bourdel-Marchasson I, Simon D: Burden of diabetes in an aging population: Prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab (2005) 31(Spec No 2):5S35-5S52.
4. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, Rahman A: No health without mental health. The Lancet (2007) 370(9590):859-877.
5. Palsson SP, Östling S, Skoog I: The incidence of first-onset depression in a population followed from the age of 70 to 85. Psychol Med (2001) 31(7):1159-1168.
6. Beekman AT, Copeland JR, Prince MJ: Review of community prevalence of depression in later life. Br J Psychiatry (1999) 174:307-311.
7. Copeland JR, Beekman AT, Dewey ME, Hooijer C, Jordan A, Lawlor BA, Lobo A, Magnusson H, Mann AH, Meller I, Prince MJ et al: Depression in Europe. Geographical distribution among older people. Br J Psychiatry (1999) 174:312-321.
8. Copeland JR, Davidson IA, Dewey ME, Gilmore C, Larkin BA, McWilliam C, Saunders PA, Scott A, Sharma V, Sullivan C: Alzheimer's disease, other dementias, depression and pseudodementia: Prevalence, incidence and three-year outcome in Liverpool. Br J Psychiatry (1992) 161:230-239.
9. Berr C, Wancata J, Ritchie K: Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol (2005) 15(4):463-471.
10. Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G et al: Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: Part I. Dement. Geriatr Cogn Disord (2007) 24(6):457-463.
11. Aalten P, Verhey FR, Boziki M, Brugnolo A, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K et al: Consistency of neuropsychiatric syndromes across dementias: Results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord (2008) 25(1):1-8.
12. Copeland MP, Daly E, Hines V, Mastromauro C, Zaitchik D, Gunther J, Albert M: Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis Assoc Disord (2003) 17(1):1-8.
13. Fuhrer R, Dufouil C, Dartigues JF, PAQUID Study: Exploring sex differences in the relationship between depressive symptoms and dementia incidence: Prospective results from the PAQUID study. J Am Geriatr Soc (2003) 51(8):1055-1063.
14. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K: Depressive symptoms, vascular disease, and mild cognitive impairment: Findings from the Cardiovascular Health Study. Arch Gen Psychiatry (2006) 63(3):273-279.
15. Modrego PJ, Ferrandez J: Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: A prospective cohort study. Arch Neurol (2004) 61(8):1290-1293.
16. Gabryelewicz T, Styczynska M, Luczywek E, Barczak A, Pfeffer A, Androsiuk W, Chodakowska-Zebrowska M, Wasiak B, Peplonska B, Barcikowska M: The rate of conversion of mild cognitive impairment to dementia: Predictive role of depression. Int J Geriatr Psychiatry (2007) 22(6):563-567.
17. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D: Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry (2006) 63(5):530-538. • A comprehensive review of the relationships between depression and AD.
18. Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M: Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatr (2008) 16(2):168-174. • This study analyzed postmortem material from patients with AD and demonstrated that specific neuropathological changes were associated with a past history of comorbid depression.
19. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, Gorman JM, Haroutunian V: Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry (2006) 63(2):161-167.
20. Verma S, Anderson TJ: Fundamentals of endothelial function for the clinical cardiologist. Circulation (2002) 105(5):546-549.
21. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C: Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol (2005) 45(9):1441-1448.
22. Newby AC: Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res (2006) 69(3):614-624.
23. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, Oliver JJ et al: Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens (2005) 23(2):233-246.
24. Behrendt D, Ganz P: Endothelial function. From vascular biology to clinical applications. Am J Cardiol (2002) 90(10C):40L-48L.
25. Landmesser U, Drexler H: The clinical significance of endothelial dysfunction. Curr Opin Cardiol (2005) 20(6):547-551.
26. Suvorava T, Lauer N, Kojda G: Physical inactivity causes endothelial dysfunction in healthy young mice. J Am Coll Cardiol (2004) 44(6):1320-1327.
27. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G et al: Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 111(18):2356-2363.
28. Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, Salvetti A: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension (2001) 37(3):943-948.
29. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D: Stimulation of endothelial progenitor cells: A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension (2005) 45(4):526-529.
30. Goligorsky MS: Clinical assessment of endothelial dysfunction: Combine and rule. Curr Opin Nephrol Hypertens (2006) 15(6):617-624.
31. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D et al: Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens (2005) 23(1):7-17.
32. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 288(5789):373-376.
33. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (1992) 340(8828):1111-1115.
34. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Lüscher TF: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 91(5):1314-1319.
35. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med (1999) 340(1):14-22.
36. Zureik M, Ducimetière P, Touboul PJ, Courbon D, Bonithon-Kopp C, Berr C, Magne C: Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: Longitudinal results from the Aging Vascular Study (EVA) study. Arterioscler Thromb Vasc Biol (2000) 20(6):1622-1629.
37. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation (1997) 96(5):1432-1437.
38. Naka KK, Tweddel AC, Doshi SN, Goodfellow J, Henderson AH: Flow-mediated changes in pulse wave velocity: A new clinical measure of endothelial function. Eur Heart J (2006) 27(3):302-309.
39. Park SM, Seo HS, Lim HE, Shin SH, Park CG, Oh DJ, Ro YM: Assessment of arterial stiffness index as a clinical parameter for atherosclerotic coronary artery disease. Circ J (2005) 69(10):1218-1222.
40. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, ter Wee PM, van Guldener C: Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int (2005) 68(5):2230-2236.
41. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: Results from the 14-year follow-up of a large cohort from southern Germany. Circulation (2004) 110(14):1903-1908.
42. Kirmizis D, Tsiandoulas A, Pangalou M, Koutoupa E, Rozi P, Protopappa M, Barboutis K: Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Med Sci Monit (2006) 12(2):CR55-CR62.
43. 2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol (2006) 26(1):106-111.
44. Jenny NS, Arnold AM, Kuller LH, Sharrett AR, Fried LP, Psaty BM, Tracy RP: Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults. J Thromb Haemost (2006) 4(1):107-113.
45. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ: Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes (2004) 53(1):195-199.
46. Horstman LL, Jy W, Jimenez JJ, Ahn YS: Endothelial microparticles as markers of endothelial dysfunction. Front Biosci (2004) 9:1118-1135.
47. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM: Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol (2005) 16(11):3381-3388.
48. Holley CK, Mast BT: The effects of widowhood and vascular risk factors on late-life depression. Am J Geriatr Psychiatry (2007) 15(8):690-698.
49. Alexopoulos GS, Young RC, Meyers BS, Abrams RC, Shamoian CA: Late-onset depression. Psychiatr Clin North Am (1988) 11(1):101-115.
50. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M: Clinically defined vascular depression. Am J Psychiatry (1997) 154(4):562-565.
51. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M: 'Vascular depression' hypothesis. Arch Gen Psychiatry (1997) 54(10):915-922.
52. Krishnan KR, Hays JC, Blazer DG: MRI-defined vascular depression. Am J Psychiatry (1997) 154(4):497-501.
53. Hackett ML, Yapa C, Parag V, Anderson CS: Frequency of depression after stroke: A systematic review of observational studies. Stroke (2005) 36(6):1330-1340.
54. Ziegelstein RC: Depression after myocardial infarction. Cardiol Rev (2001) 9(1):45-51.
55. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diabetes Care (2001) 24(6):1069-1078.
56. Salaycik KJ, Kelly-Hayes M, Beiser A, Nguyen AH, Brady SM, Kase CS, Wolf PA: Depressive symptoms and risk of stroke: The Framingham Study. Stroke (2007) 38(1):16-21.
57. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW: Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation (1996) 94(12):3123-3129.
58. Ariyo AA, Haan M, Tangen CM, Rutledge JC, Cushman M, Dobs A, Furberg CD: Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation (2000) 102(15):1773-1779.
59. Frasure-Smith N, Lespérance F, Talajic M: Depression and 18-month prognosis after myocardial infarction. Circulation (1995) 91(4):999-1005.
60. Lespérance F, Frasure-Smith N, Talajic M, Bourassa MG: Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation (2002) 105(9):1049-1053.
61. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE: Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care (1996) 19(10):1097-1102.
62. Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Roux AV, Lee HB, Lyketsos C: Examining a bidirectional association between depressive symptoms and diabetes. J Am Med Assoc (2008) 299(23):2751- 2759.
63. Camus V, Kraehenbühl H, Preisig M, Bula CJ, Waeber G: Geriatric depression and vascular diseases: What are the links? J Affect Disord (2004) 81(1):1-16.
64. Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B: Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol (2001) 88(2):196-198.
65. Broadley AJM, Korszun A, Jones CJH, Frenneaux MP: Arterial endothelial function is impaired in treated depression. Heart (2002) 88(5):521-523.
66. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA: Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol (2005) 46(4):656-659.
67. Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H: Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry (2006) 60(8):889-891.
68. Faramawi MF, Gustat J, Wildman RP, Rice J, Johnson E, Sherwin R, Cardiovascular Health Study Investigators: Relation between depressive symptoms and common carotid artery atherosclerosis in American persons > or = 65 years of age. Am J Cardiol (2007) 99(11):1610-1613.
69. Smith PJ, Blumenthal JA, Babyak MA, Hoffman BM, Doraiswamy PM, Waugh R, Hinderliter A, Sherwood A: Cerebrovascular risk factors, vascular disease, and neuropsychological outcomes in adults with major depression. Psychosom Med (2007) 69(6):578-586.
70. Dimopoulos N, Piperi C, Salonicioti A, Mitsonis C, Liappas I, Lea RW, Kalofoutis A: Elevation of plasma concentration of adhesion molecules in late-life depression. Int J Geriatr Psychiatry (2006) 21(10):965-971.
71. Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Mellédo JM: Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry (2004) 56(2):129-134.
72. Dome P, Teleki Z, Rihmer Z, Peter L, Dobos J, Kenessey I, Tovari J, Timar J, Paku S, Kovacs G, Dome B: Circulating endothelial progenitor cells and depression: A possible novel link between heart and soul. Mol Psychiatry (2008):doi:10.1038/sj.mp.4002138.
73. Thomas AJ, Ferrier IN, Kalaria RN, Woodward SA, Ballard C, Oakley A, Perry RH, O'Brien JT: Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am J Psychiatry (2000) 157(10):1682-1684.
74. Thomas AJ, Ferrier IN, Kalaria RN, Davis S, O'Brien JT: Cell adhesion molecule expression in the dorsolateral prefrontal cortex and anterior cingulate cortex in major depression in the elderly. Br J Psychiatry (2002) 181:129-134. • This study was the first to demonstrate a potential link between localized brain ischemic lesions and a past history of late onset geriatric depression.
75. Yang EH, Lerman S, Lennon RJ, Simari RD, Lerman LO, Lerman A: Relation of depression to coronary endothelial function. Am J Cardiol (2007) 99(8):1134-1136.
76. Thomas AJ, Morris C, Davis S, Jackson E, Harrison R, O'Brien JT: Soluble cell adhesion molecules in late-life depression. Int Psychogeriatr (2007) 19(5):914-920.
77. Chen CS, Chen CC, Kuo YT, Chiang IC, Ko C-H, Lin H-F: Carotid intima-media thickness in late-onset major depressive disorder. Int J Geriatr Psychiatry (2006) 21(1):36-42.
78. Delacourte A, David JP, Sergeant N, Buée L, Wattez A, Vermersch P, Ghozali F, Fallet-Bianco C, Pasquier F, Lebert F, Petit H, Di Menza C: The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology (1999) 52(6):1158-1165.
79. Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A: Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol (1998) 147(6):574-580.
80. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, Brayne C, Copeland JR, Dartigues JF, Kragh-Sorensen P, Lobo A et al: Rates and risk factors for dementia and Alzheimer's disease: Results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology (1999) 52(1):78-84.
81. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A: Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol (2005) 62(10):1556-1560.
82. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ: Enhanced risk for Alzheimer disease in persons with type 2 diabetes and ApoE ε4: The Cardiovascular Health Study Cognition Study. Arch Neurol (2008) 65(1):89-93.
83. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L: Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Neurology (2004) 63(7):1181-1186.
84. Kalaria RN: Vascular factors in Alzheimer's disease. Int Psychogeriatr (2003) 15(Suppl 1):47-52.
85. Haglund M, Englund E: Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord (2002) 14(3):161-166.
86. Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA: ApoE, vascular pathology, and the AD brain. Neurology (2005) 65(2):259-265.
87. 18F]FDG PET study. Neurology (2007) 68(7):501-508.
88. Launer LJ: Demonstrating the case that AD is a vascular disease: Epidemiologic evidence. Ageing Res Rev (2002) 1(1):61-77.
89. de la Torre JC: Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol (2004) 3(3):184-190.
90. Kawai M, Cras P, Perry G: Serial reconstruction of β-protein amyloid plaques: Relationship to microvessels and size distribution. Brain Res (1992) 592(1-2):278-282.
91. Kouznetsova E, Klingner M, Sorger D, Sabri O, Grossmann U, Steinbach J, Scheunemann M, Schliebs R: Developmental and amyloid plaque-related changes in cerebral cortical capillaries in transgenic Tg2576 Alzheimer mice. Int J Dev Neurosci (2006) 24(2-3):187-193.
92. Iadecola C: Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci (2004) 5(5):347-360.
93. Hamel E, Nicolakakis N, Aboulkassim T, Ongali B, Tong XK: Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp Physiol (2008) 93(1):116-120.
94. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C: A β-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol (2001) 281(6):H2417-H2424.
95. Park L, Anrather J, Girouard H, Zhou P, Iadecola C: Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab (2007) 27(12):1908-1918.
96. de la Torre JC, Aliev G: Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: Spatial memory and immunocytochemical changes. J Cereb Blood Flow Metab (2005) 25(6):663-672.
97. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Muller-Spahn F: Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging (2001) 22(4):541-546.
98. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB: Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging (2004) 25(3):283-290.
99. 165 with β-amyloid, and its protective effect on β-amyloid-induced neurotoxicity. J Neurochem (2005) 93(1):118-127. • This preclinical study provided strong support to the hypothesis of a potential interaction between VEGF and amyloidogenesis.
100. Qi JP, Wu H, Yang Y, Wang DD, Chen YX, Gu YH, Liu T: Cerebral ischemia and Alzheimer's disease: The expression of amyloid-β and apolipoprotein E in human hippocampus. J Alzheimers Dis (2007) 12(4):335-341.
101. Burdo JR, Chen Q, Calcutt NA, Schubert D: The pathological interaction between diabetes and presymptomatic Alzheimer's disease. Neurobiol Aging (2008):doi:10.1016/j.neurobiolaging.2008.02.010.
102. Algotsson A, Nordberg A, Almkvist O, Winblad B: Skin vessel reactivity is impaired in Alzheimer's disease. Neurobiol Aging (1995) 16(4):577-582.
103. Dede DS, Yavuz B, Yavuz BB, Cankurtaran M, Halil M, Ulger Z, Cankurtaran ES, Aytemir K, Kabakci G, Ariogul S: Assessment of endothelial function in Alzheimer's disease: Is Alzheimer's disease a vascular disease? J Am Geriatr Soc (2007) 55(10):1613-1617.
104. Janciauskiene SM, Erikson C, Warkentin S: A link between sICAM-1, ACE and parietal blood flow in the aging brain. Neurobiol Aging (2008):doi:10.1016/j.neurobiolaging.2007.08.025.
105. Nielsen HM, Londos E, Minthon L, Janciauskiene SM: Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis (2007) 26(1):27-35.
106. Hickie I, Scott E, Mitchell P, Wilhelm K, Austin MP: Subcortical hyperintensities on magnetic resonance imaging: Clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry (1995) 37(3):151-160.
107. Hickie I, Scott E, Brodaty H: Subcortical intensities on magnetic resonance imaging in patients with severe depression - A longitudinal evaluation. Biol Psychiatry (1997) 42(5):367-374.
108. Simpson S, Baldwin RC, Jackson A, Burns AS: Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med (1998) 28(5):1015-1026.
109. Steffens DC, Conway CR, Dombeck CB, Wagner HR, Tupler LA: Severity of subcortical gray matter hyperintensity predicts ECT response in geriatric depression. J ECT (2001) 17(1):45-49.
110. Steffens DC, Chung H, Krishnan KR, Longstreth WT Jr, Carlson M, Burke GL: Antidepressant treatment and worsening white matter on serial cranial magnetic resonance imaging in the elderly: The Cardiovascular Health Study. Stroke (2008) 39(3):857-862. • Data from this prospective cardiovascular health study unexpectedly suggested that the use of any type of antidepressant increased the risk of worsening WMH in MRI scans.
111. Halperin D, Reber G: Influence of antidepressants on hemostasis. Dialogues Clin Neurosci (2007) 9(1):47-59.
112. Maurer-Spurej E, Pittendreigh C, Solomons K: The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost (2004) 91(1):119-128.
113. de Abajo FJ, Garcia-Rodriguez LA: Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: Interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry (2008) 65(7):795-803.
114. van Zyl LT, Lesperance F, Frasure-Smith N, Malinin AI, Atar D, Laliberte MA, Serebruany VL: Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J Thromb Thrombolysis (2008):doi:10.1007/s11239-007-0189-3. •• This study demonstrated that the treatment of patients with depression and coronary artery disease with citalopram for 12 weeks was associated with enhanced production of NO, despite the co-administration of commonly prescribed anti-platelet regimens, including aspirin and clopidogrel.
115. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C et al: Sertraline treatment of major depression in patients with acute MI or unstable angina. J Am Med Assoc (2002) 288(6):701-709.
116. Wang JG, Staessen JA, Li Y, Bortel LMV, Nawrot T, Fagard R, Messerli FH, Safer M: Carotid intima-media thickness and antihypertensive treatment: A meta-analysis of randomized controlled trials. Stroke (2006) 37(7):1933-1940.
117. Li H, Wallerath T, Munzel T, Forstermann U: Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide (2002) 7(3):149-164.
118. Yamagishi S, Nakamura K, Matsui T: Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem (2008) 15(2):172-177.
119. Godfraind T: Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci (2005) 360(1464):2259-2272.
120. Taragano FE, Allegri R, Vicario A, Bagnatti P, Lyketsos CG: A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'. Int J Geriat Psychiatry (2001) 16(3):254-260.
121. Lopez-Arrieta JM, Birks J: Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev (2002):CD000147.
122. Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N Engl J Med (1988) 319(6):348-353.
123. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W: Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 226(4680):1342-1344.
124. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF: Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology (1994) 60(4):436-444.
125. Holsboer F: Prediction of clinical course by dexamethasone suppression test (DST) response in depressed patients - physiological and clinical construct validity of the DST. Pharmacopsychiatria (1983) 16(6):186-191.
126. Nemeroff CB, Evans DL: Correlation between the dexamethasone suppression test in depressed patients and clinical response. Am J Psychiatry (1984) 141(2):247-249.
127. Troxler RG, Sprague EA, Albanese RA, Fuchs R, Thompson AJ: The association of elevated plasma cortisol and early atherosclerosis as demonstrated by coronary angiography. Atherosclerosis (1977) 26(2):151-162.
128. Whitworth JA, Mangos GJ, Kelly JJ: Cushing, cortisol, and cardiovascular disease. Hypertension (2000) 36(5):912-916.
129. Mangos GJ, Walker BR, Kelly JJ, Lawson JA, Webb DJ, Whitworth JA: Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens (2000) 13(11):1155-1160.
130. Radomski MW, Palmer RM, Moncada S: Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA (1990) 87(24):10043-10047.
131. Wallerath T, Witte K, Schafer SC, Schwarz PM, Prellwitz W, Wohlfart P, Kleinert H, Lehr HA, Lemmer B, Forstermann U: Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci USA (1999) 96(23):13357-13362.
132. Simmons WW, Ungureanu-Longrois D, Smith GK, Smith TW, Kelly RA: Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. J Biol Chem (1996) 271(39):23928-23937.
133. Rogers KM, Bonar CA, Estrella JL, Yang S: Inhibitory effect of glucocorticoid on coronary artery endothelial function. Am J Physiol Heart Circ Physiol (2002) 283(5):H1922-H1928.
134. Johns DG, Dorrance AM, Tramontini NL, Webb RC: Glucocorticoids inhibit tetrahydrobiopterin-dependent endothelial function. Exp Biol Med (Maywood) (2001) 226(1):27-31.
135. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R, Canick J: Antiglucocorticoid treatment of depression: Double-blind ketoconazole. Biol Psychiatry (1999) 45(8):1070-1074.
136. Murphy BE, Filipini D, Ghadirian AM: Possible use of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU486. J Psychiatry Neurosci (1993) 18(5):209-213.
137. O'Dwyer AM, Lightman SL, Marks MN, Checkley SA: Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord (1995) 33(2):123-128.
138. Broadley AJ, Korszun A, Abdelaal E, Moskvina V, Deanfield J, Jones CJ, Frenneaux MP: Metyrapone improves endothelial dysfunction in patients with treated depression. J Am Coll Cardiol (2006) 48(1):170-175.
139. Wegener G, Volke V, Harvey BH, Rosenberg R: Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res (2003) 959(1):128-134.
140. 2A/C-receptors. Metab Brain Dis (2006) 21(2-3):211-220.
141. Dhir A, Kulkarni SK: Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol (2007) 568 (1-3):177-185.
142. Dhir A, Kulkarni SK: Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog Neuropsychopharmacol Biol Psychiatry (2007) 31(4):921-925. • This preclinical study demonstrated that the antidepressant-like effect of venlafaxine involved the L-Arg-NO- cGMP pathway.
143. Heiberg IL, Wegener G, Rosenberg R: Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res (2002) 134(1-2):479-484.
144. Kulkarni SK, Dhir A: Possible involvement of L-arginine- nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. Eur J Pharmacol (2007) 569(1-2):77-83.
145. Harkin A, Connor TJ, Burns MP, Kelly JP: Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol (2004) 14(4):274-281.
146. Brink CB, Clapton JD, Eagar BE, Harvey BH: Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: Evidence from behavioural and neuro-receptor studies. J Neural Transm (2008) 115(1):117-125.
147. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology (2005) 69(Suppl 3):4-10.
148. Fabel K, Fabel K, Tam B, Kaufer D, Baiker A, Simmons N, Kuo CJ, Palmer TD: VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci (2003) 18(10):2803-2812. • This preclinical study demonstrated that peripheral VEGF mediated the effects of running on adult hippocampal neurogenesis.
149. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA: Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA (2002) 99(18):11946- 11950.
150. Sun Y, Jin K, Childs JT, Xie L, Mao XO, Greenberg DA: Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: Evidence from knockout mice and growth factor administration. Dev Biol (2006) 289(2):329-335. • This preclinical study suggested a role for VEGFB in the regulation of adult neurogenesis, as demonstrated by the impaired neurogenesis in VEGFB-KO mice; intraventricular administration of VEGFB restored neurogenesis to wild-type levels in VEGFB-KO mice.
151. Warner-Schmidt JL, Duman RS: VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol (2008) 8(1):14-19.
152. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (2003) 301(5634):805-809.
153. Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G, Hen R, Belzung C: Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry (2008) 64(4):293-301.
154. Warner-Schmidt JL, Duman RS: VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA (2007) 104(11):4647-4652.
155. Kim CW, Son KN, Choi SY, Kim J: Human lactoferrin upregulates expression of KDR/Flk-1 and stimulates VEGF-A-mediated endothelial cell proliferation and migration. FEBS Lett (2006) 580(18):4332- 4336.
156. Winblad B, Fioravanti M, Dolezal T, Logina I, Milanov IG, Popescu DC, Solomon A: Therapeutic use of nicergoline. Clin Drug Investig (2008) 28(9):533-552.
157. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J: Therapeutic approaches to Alzheimer's disease. Brain (2006) 129(Pt 11):2840-2855.
158. Rosengarten B, Paulsen S, Burr O, Kaps M: Neurovascular coupling in Alzheimer patients: Effect of acetylcholineesterase inhibitors. Neurobiol Aging (2008): doi:10.1016/j.neurobiolaging.2008.02.017.
159. Bar KJ, Boettger MK, Seidler N, Mentzel HJ, Terborg C, Sauer H: Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy. Stroke (2007) 38(12):3186-3192.
160. Kavirajan H, Schneider LS: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials. Lancet Neurol (2007) 6(9):782-792.
161. Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD: Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ (2008) 178(5):548-556.
162. Lange-Asschenfeldt C, Kojda G: Alzheimer's disease, cerebrovascular dysfunction and the benefits of exercise: From vessels to neurons. Exp Gerontol (2008) 43(6):499-504.
163. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE: NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ 42 in vivo. J Clin Invest (2003) 112(3):440-449.
164. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE et al: A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature (2001) 414(6860):212-216.
165. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, Zandi PP: NSAID use and dementia risk in the Cardiovascular Health Study: Role of APOE and NSAID type. Neurology (2008) 70(1):17-24.
166. Schultheiss C, Blechert B, Gaertner FC, Drecoll E, Mueller J, Weber GF, Drzezga A, Essler M: In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease. Angiogenesis (2006) 9(2):59-65.